Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Treasury Shares (2025)

Crinetics Pharmaceuticals has reported Treasury Shares over the past 1 years, most recently at $112000.0 for Q4 2025.

  • For Q4 2025, Treasury Shares changed N/A year-over-year to $112000.0; the TTM value through Dec 2025 reached $112000.0, changed N/A, while the annual FY2025 figure was $112000.0, N/A changed from the prior year.
  • Treasury Shares for Q4 2025 was $112000.0 at Crinetics Pharmaceuticals, roughly flat from $112000.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $112000.0 in Q2 2025 and troughed at $112000.0 in Q2 2025.